Specialty pharmaceutical company A.P. Pharma today announced that the U.S. Patent and Trademark Office (USPTO) has allowed three new patents covering APF530, the company’s lead product candidate for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).
A.P. Pharma president and CEO John B. Whelan called the patents “instrumental” in augmenting the product’s overall patent life, which will extend through 2024.
“A.P. Pharma continues to make advancements related to APF530 beyond clinical and regulatory development, and the allowance of these patents provides added strength to the APF530 patent estate and will help support the product’s longevity,” Whelan stated in the press release.
The company offered the following details on patent coverage:
• U.S. Patent application number 13/279,949, entitled “Process for Preparing a Semi-Solid Delivery Vehicle Comprising Granisetron,” relates to methods for preparing extended release formulations of granisetron.
• U.S. Patent application number 13/279,938, entitled “Methods of Treating Emesis Utilizing Semi-Solid Pharmaceutical Compositions Comprising Granisetron,” relates to methods for the treatment of emesis using extended release formulations of granisetron.
• U.S. Patent application number 12/564,881, entitled “Semi-Solid Delivery Vehicle and Pharmaceutical Compositions for Delivery of Granisetron,” relates to compositions for extended delivery of granisetron.
For more information visit www.appharma.com
Let us hear your thoughts below: